Abstracts tagged "cytokines"

Abstract Number: 1771 • ACR Convergence 2021
First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8
Melanie Harrison¹, Manoj Chiney¹, Diane Shevell², Lixian Dong³, Michelle Dawes¹ and Ihab Girgis³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Lawrenceville, ³Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Toll-like receptor (TLR)7 and TLR8 are endosomal receptors that are normally activated by pathogen-associated RNA. They are also activated by self-RNA as part of…
Abstract Number: 0032 • ACR Convergence 2021
IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
Adela Navratilova¹, Lucie Andrés Cerezo¹, Hana Hulejová², Viktor Bečvář², Michal Tomcik³, Dana Tegzova², Martina Olejárová¹, David Veigl⁴, Karel Pavelka³, Jiri Vencovsky² and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴First Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…
Abstract Number: 1008 • ACR Convergence 2021
Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
Amita Aggarwal, Sanjukta Majumder and Shivika Guleria, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-36 has been implicated in the pathogenesis of spondyloarthropathies (SpA) like psoriasis and IBD. Enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA)…
Abstract Number: 1837 • ACR Convergence 2021
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
Yu-Hsiang Chiu¹, Mareye Voortman¹, Eveline Delemarre¹, Stefan Nierkens¹, Pim de Jong¹, Firdaus Mohamed Hoesein¹, Jan Grutters², Jacob van Laar¹ and Julia Spierings³, ¹University Medical Centre Utrecht, Utrecht, Netherlands, ²St. Antonius Hospital, Nieuwegein, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in…
Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
Abstract Number: 1011 • ACR Convergence 2021
Validation of Bioinformatics Pipeline to Detect NEMO-Deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) and Preliminary Clinical and Immunologic Characterization
Adriana Almeida de Jesus¹, Bin Lin², Eric Karlins³, Dana Kahle⁴, Andre Rastegar², Jacob Mitchell², Sofia Torreggiani², Farzana Bhuyan², Sara Alehashemi⁵, Kader Cetin Gedik⁶, Kat Uss², Chyi-Chia Lee⁷, Hyesun Kuehn⁸, Sergio Rosenzweig⁸, Katherine Calvo⁸, Magdalena Walkiewicz⁹, Justin Lack¹⁰, Eric Hanson¹¹, Amer Khojah¹², Eveline Wu¹³, Christiaan Scott¹⁴, Timothy Ronan Leahy¹⁵, Emma MacDermott¹⁵, Orla Kileen¹⁵, Thaschawee Arkachaisri¹⁶, Zoran Gucev¹⁷, Kathryn Cook¹⁸, Vafa Mammadova¹⁹, Gulnara Nasrullayeva¹⁹, Scott Canna²⁰, Douglas Kuhns²¹, Clifton Dalgard²², Timothy Moran²³, Andrew Oler³ and Raphaela Goldbach-Mansky²⁴, ¹TADS/NIAID/NIH, Silver Spring, MD, ²TADS/NIAID/NIH, Bethesda, MD, ³BCBB/NIAID/NIH, Bethesda, MD, ⁴National Institutes of Health, Chevy Chase, MD, ⁵TADS/NIAID/NIH, Clarksville, MD, ⁶Translational Autoinflammatory Diseases Section (TADS)/NIAID/NIH, Bethesda, MD, ⁷NCI/NIH, Bethesda, MD, ⁸CC/DLM/NIH, Bethesda, MD, ⁹CSI/NIAID/NIH, Bethesda, MD, ¹⁰NCBR/NIAID/NIH, Bethesda, MD, ¹¹Indiana University School of Medicine, Indianapolis, IN, ¹²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹³UNC Chapel Hill, Chapel Hill, NC, ¹⁴Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ¹⁵Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, ¹⁶KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹⁷University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ¹⁸Akron Childrens Hospital, Copley, OH, ¹⁹Azerbaijan Medical University, Baku, Azerbaijan, ²⁰Children's Hospital of Philadelphia, Philadelphia, PA, ²¹Frederick National Laboratory for Cancer Research/NIH, Frederick, MD, ²²TAGC/USUHS, Bethesda, MD, ²³University of North Carolina School of Medicine, Chapel Hill, NC, ²⁴NIH/NIAID, Potomac, MD
Background/Purpose: Splice site variants in IKBKG that lead to exon 5 deletion cause NEMO-deleted exon 5 autoinflammatory syndrome (NEMO-NDAS). NEMO-NDAS clinically mimics the interferonopathy chronic…
Abstract Number: 1905 • ACR Convergence 2021
CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
Jennifer Barnas¹, Jennifer Barnard², Cameron Baker², Nida Meednu², Andrew McDavid¹, R. John Looney¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…
Abstract Number: 0050 • ACR Convergence 2021
Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis
Maricela Haghiac¹, Maya Breitman², Ricky Chan³, Ahmad Khalil³ and Marina Magrey⁴, ¹Metrohealth Medical center, Cleveland, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH
Background/Purpose: Gender has been shown to impact disease expression in ankylosing spondylitis. Men with AS are more likely to develop radiographic joint damage, while women…
Abstract Number: 1012 • ACR Convergence 2021
Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis
Serena Foo¹, Achilleas Floudas², Aisling O' Brien¹, Sharon Ansboro¹, Ronan Mullan³, Douglas Veale⁴, Emma MacDermott⁵, Derek Deely⁶, Charlene Foley⁶, Orla Killeen⁶ and Ursula Fearon¹, ¹Trinity College Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ³Tallaght University Hospital, Dublin, Ireland, ⁴University College Dublin, Dublin, Ireland, ⁵Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, ⁶Children's Health Ireland, Crumlin, Dublin, Ireland
Background/Purpose: Juvenile idiopathic arthritis (JIA) was thought to be the most common inflammatory arthritis in children. However an aggressive, erosive arthritis of little-known immunologic mechanism…
Abstract Number: L07 • ACR Convergence 2020
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
John Stone¹, ¹Massachusetts General Hospital, Boston, MA
Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
Abstract Number: 0003 • ACR Convergence 2020
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Quinn Pritchett¹, Rebecca Overbury¹, Dorota Lebiedz-Odrobina¹, Julie Thomas¹, Tawnie Braaten², Stacey Clardy¹, Marc Elgort³, Emily Spivak¹, Patricia Slev³, Lisa Peterson³ and Tracy Frech⁴, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, ³ARUP, Salt Lake City, UT, ⁴University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
Abstract Number: 0791 • ACR Convergence 2020
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari¹, Takeo Isozaki¹, Kuninobu Wakabayashi¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 0065 • ACR Convergence 2020
The Energy-dependent Hierarchy of Immune Functions in Human Monocytes
Pierre-Louis Krauß¹, Thomas Buttgereit², Yuling Chen¹, Moritz Pfeiffenberger¹, Timo Gaber¹ and Frank Buttgereit³, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology, and Allergology, Berlin, Germany, ³Charité University Medicine, Berlin, Germany
Background/Purpose: At sites of inflammation, monocytes carry out specific immunological functions while facing challenging bioenergetic restrictions. Here, we investigated the potential of human monocytes to…
Abstract Number: 0851 • ACR Convergence 2020
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
Peter Lipsky¹, Ronald van Vollenhoven², Thomas Dörner³, Victoria Werth⁴, Joan Merrill⁵, Richard Furie⁶, Milan Petronijevic⁷, Benito Velasco Zamora⁸, Maria Majdan⁹, Fedra Irazoque-Palazuelos¹⁰, Robert Terbrueggen¹¹, Nikolay Delev¹², Michael Weiswasser¹², Shimon Korish¹², Nataliya Agafonova¹², Mark Stern¹³, Sarah Hersey¹³, Ying Ye¹³, Allison Gaudy¹², Zhaohui Liu¹², Shaojun Tang¹³ and Peter Schafer¹², ¹RILITE Foundation, Charlottesville, VA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³DRFZ and Charité University Hospitals, Berlin, Germany, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷Military Medical Academy, Belgrade, Serbia, ⁸Instituto CER S.A., Buenos Aires, Argentina, ⁹Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ¹⁰Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ¹¹DxTerity Diagnostics Inc, Rancho Dominguez, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol-Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].